Hat hier irgend jemand Neurocrine Biosciences?? - 500 Beiträge pro Seite

[MichaelMyers]

hi,

was haltet ihr von dem wert??
am wochenende kamen ganz gute news raus!
also ich glaube, dass neurocrine eine
vielversprechende aktie ist!!
was meint ihr?

cya

[Guru-Schreck]

Ein toller Aufwärtstrend den Neurocrine da herausgebildet hat.

[interspeed1]

hier mal ein Chart





Gruß

[Geko007]

RESEARCH ALERT-Neurocrine upped to strong buy
May 21, 2001 7:41am


NEW YORK, May 21 (Reuters) - Robertson Stephens analyst Michael King Jr. raised his rating on drug company Neurocrine Biosciences Inc. <NBIX.O> to strong buy from buy on Monday.

He said the "company`s transition into a late-stage product story is imminent."

King added, "The advantages its insomnia drug has over existing drugs continues to become more apparent" and "though early, the CRF program for depression/anxiety has enormous potential."

He said Neurocrine would "enjoy increasing visibility from positive near-term drivers, including clinical trial results and pipeline progress."

Neurocrine shares closed on Friday at $31.44.

((-- Wall Street desk, [phone], fax [phone]))

VIEL SPASS,bin seit 06/00 und 18 Euro dabei!!!

Geko007

[Geko007]

Hier nochwas :

Oklahoma Foundation for Digestive Research Reports Pre-Clinical Efficacy Of CRF1 Receptor Antagonists for Irritable Bowel Syndrome;Data Will Be Presented and Highlighted At the Digestive Diseases Week Meeting In Atlanta, GA, May 20-23
May 20, 2001 10:50am

ATLANTA, May 20, 2001 /PRNewswire via COMTEX/ -- Oklahoma Foundation for Digestive Research (OFDR)-Basic Science Lab announced today that they will report on preclinical efficacy data in irritable bowel syndrome (IBS) from a study conducted with a small molecule CRF1 receptor antagonist at the Digestive Diseases Week (DDW) meeting on Sunday, May 20, 2001. In the preclinical study, conducted by Dr. Greenwood-Van Meerveld, Scientific Director of OFDR, administration of a CRF1 receptor antagonist developed by Neurocrine Biosciences was highly effective in a model of the pain and discomfort that is experienced by IBS patients. IBS is a disturbance of function of the lower intestine and colon, affecting 15-20% of the population, mainly women. IBS is characterized by three primary symptoms, altered gastrointestinal function, visceral pain or discomfort and bloating. In the study, oral administration of the compound produced a dose-dependent relief of experimentally induced visceral discomfort, with a significant effect at 0.1 mg/kg (50% response), and at higher doses responses were restored to baseline (100% response).

Numerous studies have shown a close relationship between stress resulting from life events or psychiatric disturbance and the onset and severity of IBS symptoms. Recent studies have suggested that CRF, which is believed to be a primary mediator of stress, plays an important role in the control or modulation of the gastrointestinal system. These new data suggest that CRF1 receptor antagonists may provide a new therapeutic intervention for irritable bowel syndrome, a very large and underserved market.

Dr. Greenwood-Van Meerveld commented, "The effects of Neurocrine`s CRF1 receptor antagonist in our visceral hypersensitivity model were most impressive. CRF1 receptor antagonists represent an entirely new approach to the treatment of IBS, a disease which is in desperate need of effective therapies."

Neurocrine Biosciences, Inc, based in San Diego, California, is the world leader in the CRF field through its broad intellectual property portfolio and relationships with experts in the neuropsychiatric field. A single dose Phase I safety study has been successfully completed with Neurocrine`s lead CRF receptor antagonist clinical compound.

Background

According to the International Foundation for Gastrointestinal Disorders (IFFGD), IBS is the most common GI disorder affecting an estimated 15-20% of adults. A substantial proportion of patient visits to primary care physicians for gastrointestinal complaints and referrals to gastroenterologists are for IBS. It is a disorder that affects the nerves and muscles of the bowel, and causes abdominal pain, irregular bowel movements, and can cause deep personal distress. Painful attacks can last from a matter of days to several months. In many cases, the cause is unknown, but stress, diet and infection can bring on or aggravate symptoms. The social and economic costs of functional GI disorders are enormous and represent an important health care burden. The symptoms of IBS heavily impact patients` lifestyles. IBS is a leading cause of worker absenteeism, second only to the common cold, with an average of 13.4 missed workdays a year among IBS patients. The disease has been estimated to result in $10.5 billion in excess direct medical expenses compared to control subjects annually in the US. Approximately 70% of IBS cases are reported in women, making this a major women`s health issue and in addition is becoming one of the most common diseases in the elderly. Data has revealed that women with IBS have an increased risk of unnecessary surgery; hysterectomy or ovarian surgery and these are performed more often in IBS patients than in other comparative groups. IBS does not show any evidence of an organic or physical disease, and the cause of a functional GI disorder does not show up in traditional laboratory examinations such as blood tests or x-rays. For this reason, IBS is an under diagnosed disorder, and was formerly a "diagnosis of exclusion", meaning that it was observed only after diagnostic tests had excluded other causes. But over the past two decades, medical opinion has changed with regard to the diagnosis of IBS and an evaluation known as the "Rome II" criteria has become increasingly used by physicians to diagnose this debilitating disease.



MAKE YOUR OPINION COUNT - Click Here

HTTP://TBUTTON.PRNEWSWIRE.COM/PRN/11690X62454011

SOURCE Oklahoma Foundation for Digestive Research



CONTACT: Beverly Greenwood-Van Meerveld, Ph.D, of Oklahoma Foundation
For Digestive Research, 405-270-0501, ext. 3547; or Alan Foster, PhD, of
Neurocrine Biosciences, 858-349-2666

[mr.lukoil]

Hallo,
sehr schoenen Überblick über die Produktpalette gibt es im letzten Quartalsbericht. Wenn ich mich richtig erinnere waren es insgesamt zwischen 12 und 16 Medikamente, die in der pipeline waren.
Ausserdem auch eine kleinere Beteiligung von bb biotech.
Halte die Aktie auch für aussichtsreich. Kostete im letzten Jahr allerdings gut Nerven.
Viel ERfolg

lukoil

[Geko007]

ja,das mit bb bioteh stimmt,habe ich schon im letzten jaht gepostet,und bb biotech hat schon gute "nase",also,vieleht landet neurocrina einen blockbuster weil die bewertung momentan ist auch nicht ohne fuer eine firma ohne produkte auf dem markt,953 Milionen $.

gruss geko007

[Guru-Schreck]

Tuesday June 26, 7:00 pm Eastern Time

Press Release

SOURCE: MediChem Life Sciences; Neurocrine Biosciences

MediChem and Neurocrine Biosciences Sign Proteomics Agreement on GPCR Drug
Target for Depression, Anxiety

CHICAGO and SAN DIEGO, June 26 /PRNewswire/ -- MediChem Life Sciences (Nasdaq: MCLS - news), a Chicago-based drug discovery
technology and services company, and Neurocrine Biosciences (Nasdaq: NBIX - news), a San Diego-based biopharmaceutical discovery and
development company, announced today that they have entered into a two-year collaborative agreement in proteomics for new drug development. The
announcement was made at the BIO 2001 conference in San Diego, California.

Under the terms of this renewable agreement, MediChem will crystallize and determine high-resolution 3D structures of specific G-protein coupled
receptors (GPCRs), known as CRF-1 receptors. MediChem will attempt to crystallize the receptors alone and in complex with ligands provided by
Neurocrine. Preliminary studies have shown that Neurocrine`s proprietary CRF-1 receptor antagonists may be effective in depression, anxiety and
irritable bowel syndrome (IBS).

``This powerful, new collaboration with Neurocrine shows both the potential and direct applicability of structural proteomics, and the exciting things we
are doing with these technologies at MediChem,`` said Michael T. Flavin, Ph.D., MediChem`s president and CEO. ``We are working with clients to
develop important new drugs that fight diseases affecting millions of people worldwide in a more timely fashion.``

``Neurocrine is a leader in the CRF area and already has a clinical candidate and many advanced leads being studied as potential new treatments for
depression, anxiety, and IBS,`` said John Saunders, Neurocrine`s vice president, Research (Chemistry). ``We are excited to begin collaborative efforts
with MediChem to advance our understanding of the structure of the CRF receptor and hence of second generation antagonists.``

The collaboration will start from clones and ligands provided by Neurocrine. MediChem`s Emerald BioStructures division will provide its
EmeraldEngine(TM) structural proteomics platform of technologies and services, including: protein production, purification and crystallization, as well as
X-ray diffraction data collection, crystallographic computations, and three-dimensional model building and refinement.

In consideration for work outlined in the agreement, MediChem will receive access fees, FTE funding, payments for completion of specified milestone
events, and rights to technology, data and improvements surrounding its GPCR/high-throughput structural proteomics platform.

``GPCRs are the most important and potentially the most bountiful source of new drug targets,`` Flavin said. ``Membrane proteins are the `Holy Grail` of
structural biology. They represent a true challenge because they are very difficult to crystallize. MediChem, however, has the technology and expertise
to accomplish this goal.``

GPCRs

GPCRs are one of the largest families of proteins encoded by human DNA, and are implicated in a number of diseases, including Parkinson`s,
Alzheimer`s, asthma, myocardial ischaemia, hypertension, and cognitive impairment.

It is estimated that there are more than 1,000 GPCRs with potential human therapeutic value, yet only a relative few are currently being used as drug targets. Even so, more than 30
percent of drugs currently on the market act against this class of receptor. Drugs that target GPCRs account for more than $20 billion in annual sales.

GPCRs are membrane bound proteins, which are on the surface of cells making them the most accessible proteins for drug interaction. Using structural information derived through
proteomics technologies such as MediChem`s, scientists are able to visualize the drug compounds that will be the most effective against the target protein and have the least side effects --
a process known as structure-based drug design.

Craig Behnke, Ph.D., joined MediChem as a Research Scientist in Crystallography in December 2000. Behnke was part of the team that determined the crystal structure for rhodopsin,
the first GPCR to be solved. The results were published as the cover story of the journal Science, on August 4, 2000.

X-ray Crystallography

MediChem has a proprietary user agreement with Argonne National Laboratory`s Advanced Photon Source (APS) -- one of the world`s most powerful X-ray beams. The agreement
gives MediChem scientists access to the APS to collect proprietary X-ray diffraction data for its clients` projects. This process reduces the time needed to determine a protein`s
three-dimensional structure and thus accelerates the drug candidate identification process.

MediChem scientists translate the X-ray diffraction patterns into a high resolution rendering of the three-dimensional structure of its clients` target proteins. Determining the structure of a
protein, once crystallized, used to take months or years; it may now take only a fraction of this time using MediChem`s resources. Solving a protein`s structure improves scientists` ability
to optimize small molecule drugs that are directed toward the specific target, with the goal of developing safer and more effective drugs to treat disease.

MediChem Life Sciences ( www.medichem.com ) is a drug discovery technology and services company that offers a broad range of integrated chemistry R&D capabilities to
pharmaceutical and biotechnology companies. A leader in medicinal chemistry research since its inception in 1987, MediChem has extended its technologies and services through
proteomics, biocatalysis, combinatorial chemistry and chemical process development. The company`s technologies and services are designed to enable its clients to reduce overall
development time and costs, and to advance a greater number of discovery and development opportunities through to the marketplace.

Neurocrine Biosciences ( www.neurocrine.com ) is a biopharmaceutical company focused on the discovery and development of novel therapeutics for neuropsychiatric,
neuroinflammatory and neurodegenerative diseases and disorders. The company`s neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the
molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, multiple sclerosis, insomnia, brain
cancer, obesity and diabetes.

Except for any historical information presented herein, this release contains forward-looking statements regarding MediChem`s future activities within the meaning of the Private Securities
Litigation Reform Act of 1995 and involve a high degree of risk and uncertainty. These forward-looking statements involve material risks and uncertainties. Many possible factors could
affect future results and performance of MediChem`s services and technologies, such that actual results and performance may differ materially. If MediChem`s services and technologies
fail to perform as expected or if there is lower demand for these than expected, MediChem`s financial condition and operating results may be materially and adversely affected.
MediChem`s financial condition and operating results may also be materially and adversely affected by a number of other factors, including, but not limited to, adverse changes in
competitive and economic conditions, or difficulties and adverse actions by third parties and licensors, as well as other risks identified in MediChem`s registration statement on Form S-1
filed with the Securities and Exchange Commission.

SOURCE: MediChem Life Sciences; Neurocrine Biosciences